Figure 1.

BIRC6 expression is positively correlated with EGFR and associated with poor survival in TNBC

(A) Gene set enrichment analysis was performed in the TCGA breast cancer dataset (n = 1,222) with R package “fgsea.” (B) Cells harboring an inducible EGFR-specific shRNA were treated with doxycycline hyclate for the indicated times, and the indicated proteins were detected by immunoblotting. (C) The expression profiles of BIRC6 and EGFR in eight TNBC and seven non-TNBC cell lines plus two breast normal cell lines were assessed by immunoblotting. The cell lines with high expression of EGFR are indicated in red. (D) Representative IHC staining for BIRC6 and EGFR in 90 tumor samples from TNBC patients. Case J07A2470 and Case J07A2313 are representative of a TNBC patient with BIRC6 and EGFR double high expression or double low expression, respectively. (E) Correlation between BIRC6 and EGFR expression in 90 tumor samples from TNBC patients. (F and G) Kaplan-Meier curves for OS (F) and RFS (G) in breast cancer patients with different BIRC6 expression. Patients were grouped into BIRC6-low or BIRC6-high based on the BIRC6 mRNA expression value.